Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of TriVascular Technologies Inc (NASDAQ: TRIV) acted responsibly on behalf of investors’ profitability in the planned $211 million sale to Endologix Inc (NASDAQ: ELGX).

On October 26, 2015, TriVascular Technologies Inc (NASDAQ: TRIV) and Endologix Inc (NASDAQ: ELGX) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Endologix Inc will offer TriVascular Technologies Inc shareholders $9.10 per share in cash for all outstanding shares.

Based in Santa Rosa, California, and founded in 2007 TriVascular Technologies Inc is a medical device company, which develops technologies to enhance minimally invasive treatment of abdominal aortic aneurysms.

The investigation is looking to uncover whether TriVascular Technologies Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $13.00 per share.

If you purchased TriVascular Technologies Inc (NASDAQ: TRIV) prior to October 26, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185